MRK's Winrevair Phase III Study in Newly Diagnosed PAH Meets Goal
unknown
📅 Published: 2025-06-24 16:20
📰 Source: Yahoo
📝 Words: 17
📝 Article Content
Merck's Winrevair meets goal in a phase III study in newly diagnosed PAH patients, showing strong efficacy.
📄 Summary
Merck's Winrevair meets goal in a phase III study in newly diagnosed PAH patients, showing strong efficacy.
Scraping Metadata:
Scraped At:
Unknown
Created At:
2025-06-25 06:04:27
Updated At:
2025-06-25 06:04:27
Scraping Job ID:
N/A
Stock Mentions:
MRK - Merck & Co. Inc.
Relevance: N/A